- Home
- REGN vs CIEN Comparison
REGN vs CIEN Comparison
Compare REGN & CIEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | REGN | CIEN |
|---|---|---|
| Founded | 1988 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Telecommunications Equipment |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.8B | 56.2B |
| IPO Year | 1995 | 1996 |
Fundamental Metrics
Financial Performance| Metric | REGN | CIEN |
|---|---|---|
| Price | $807.20 | $459.59 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 25 | 14 |
| Target Price | ★ $830.16 | $382.69 |
| AVG Volume (30 Days) | 766.3K | ★ 2.1M |
| Earning Date | 04-29-2026 | 06-04-2026 |
| Dividend Yield | ★ 0.55% | N/A |
| EPS Growth | 8.19 | ★ 46.55 |
| EPS | ★ 18.95 | 2.52 |
| Revenue | ★ $5,872,227,000.00 | $4,769,507,000.00 |
| Revenue This Year | $12.45 | $30.83 |
| Revenue Next Year | $10.13 | $19.87 |
| P/E Ratio | ★ $42.11 | $171.45 |
| Revenue Growth | ★ 20.82 | 18.79 |
| 52 Week Low | $541.00 | $84.41 |
| 52 Week High | $821.11 | $637.51 |
Technical Indicators
Market Signals| Indicator | REGN | CIEN |
|---|---|---|
| Relative Strength Index (RSI) | 79.05 | 60.00 |
| Support Level | $738.17 | $457.71 |
| Resistance Level | $818.06 | $497.90 |
| Average True Range (ATR) | 21.90 | 27.27 |
| MACD | 6.77 | 9.99 |
| Stochastic Oscillator | 96.32 | 97.02 |
Price Performance
Historical ComparisonAbout REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
About CIEN Ciena Corporation
Ciena is a leader in high-speed optical connectivity, providing systems, components, and automation software for telecom providers and enterprises, such as data centers, to enable long-distance connectivity. The company operates through four primary business segments: networking platforms, platform software and services, Blue Planet automation software, and global services. While telecom carriers remain important customers, cloud providers and hyperscalers now drive a significant portion of the business. To meet the demands of AI data centers, customers are adopting Ciena's WaveLogic 6 platform, the first to support 1.6 terabits-per-second capacity.